{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NKTR-214+%28Cohort+A%29",
    "query": {
      "intervention": "NKTR-214 (Cohort A)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T19:32:01.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02869295",
      "title": "A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "NKTR-214",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2015-12",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-07-29",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Portland, Oregon • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02869295"
    },
    {
      "nct_id": "NCT03138889",
      "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-214",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2017-06-09",
      "completion_date": "2022-08-24",
      "has_results": true,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 23,
      "location_summary": "Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03138889"
    },
    {
      "nct_id": "NCT03835533",
      "title": "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-214 (Cohort A)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab (Cohort A, B and C)",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic body radiation therapy (SBRT) (Cohort B)",
          "type": "RADIATION"
        },
        {
          "name": "CDX-301 (Cohort B and C)",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC (Cohort B)",
          "type": "DRUG"
        },
        {
          "name": "INO-5151 (Cohort C)",
          "type": "DRUG"
        },
        {
          "name": "Cellectra 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "Parker Institute for Cancer Immunotherapy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 43,
      "start_date": "2019-06-21",
      "completion_date": "2022-10-03",
      "has_results": true,
      "last_update_posted_date": "2024-04-12",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03835533"
    },
    {
      "nct_id": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "NKTR-262",
          "type": "DRUG"
        },
        {
          "name": "bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-03-15",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435640"
    },
    {
      "nct_id": "NCT04955262",
      "title": "A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin (NKTR-214)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "⁸⁹Zr-Df-IAB22M2C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-08",
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955262"
    },
    {
      "nct_id": "NCT04730349",
      "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ependymoma",
        "Ewing Sarcoma",
        "High-grade Glioma",
        "Leukemia and Lymphoma",
        "Medulloblastoma",
        "Miscellaneous Brain Tumors",
        "Miscellaneous Solid Tumors",
        "Neuroblastoma",
        "Relapsed, Refractory Malignant Neoplasms",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NKTR-214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-06-03",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • St Louis, Missouri",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730349"
    },
    {
      "nct_id": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Triple Negative Breast Cancer",
        "HR+/HER2- Breast Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2016-12-19",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-09-30T19:32:01.368Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983045"
    }
  ]
}